Errata Corrige

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results

Department of Pediatrics, BMT Service, Memorial Sloan Kettering Cancer Center, New York;Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York
Bone Marrow and Hematopoietic Stem Cell Transplant Program, Weill Cornell Medicine/New York Presbyterian Hospital, New York
Bone Marrow and Hematopoietic Stem Cell Transplant Program, Weill Cornell Medicine/New York Presbyterian Hospital, New York
Sickle Cell Program, Division of Hematology, Albert Einstein College of Medicine, Bronx
Lindsley F. Kimball Research Institute, New York Blood Center, NY
Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York
Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, NY
Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, NY
Lindsley F. Kimball Research Institute, New York Blood Center, NY
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Lindsley F. Kimball Research Institute, New York Blood Center, NY
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York
Sickle Cell Program, Division of Hematology, Albert Einstein College of Medicine, Bronx;Lindsley F. Kimball Research Institute, New York Blood Center, NY
Vol. 103 No. 9 (2018): September, 2018 https://doi.org/10.3324/haematol.2018.199414